Open AccessRelationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine
Author(s) -
Ahmed B. Bayoumy,
Chris J. Mulder,
A Loganayagam,
Jeremy Sanderson,
Simon Anderson,
Paul J. Boekema,
Luc J. J. Derijks,
Azhar Ansari
Publication year - 2021
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000869
Subject(s) - thiopurine methyltransferase , medicine , interquartile range , gastroenterology , inflammatory bowel disease , genotype , cohort , retrospective cohort study , adverse effect , azathioprine , disease , biology , gene , biochemistry
In inflammatory bowel disease (IBD), conventional thiopurine users cease treatment in 60% of cases within 5 years, mostly because of adverse events or nonresponse. In this study, the authors aimed to investigate the role of 6-thioguanine nucleotide (TGN) measurements, geno/phenotyping of thiopurine S-methyltransferase (TPMT), and their mutual relationship with TG therapy in IBD.